Literature DB >> 15578097

TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Dagmar Stoiber1, Boris Kovacic, Christian Schuster, Carola Schellack, Marina Karaghiosoff, Rita Kreibich, Eva Weisz, Michaela Artwohl, Olaf C Kleine, Mathias Muller, Sabina Baumgartner-Parzer, Jacques Ghysdael, Michael Freissmuth, Veronika Sexl.   

Abstract

Aberrant activation of the JAK-STAT pathway has been implicated in tumor formation; for example, constitutive activation of JAK2 kinase or the enforced expression of STAT5 induces leukemia in mice. We show here that the Janus kinase TYK2 serves an opposite function. Mice deficient in TYK2 developed Abelson-induced B lymphoid leukemia/lymphoma as well as TEL-JAK2-induced T lymphoid leukemia with a higher incidence and shortened latency compared with WT controls. The cell-autonomous properties of Abelson murine leukemia virus-transformed (A-MuLV-transformed) TYK2(-/-) cells were unaltered, but the high susceptibility of TYK2(-/-) mice resulted from an impaired tumor surveillance, and accordingly, TYK2(-/-) A-MuLV-induced lymphomas were easily rejected after transplantation into WT hosts. The increased rate of leukemia/lymphoma formation was linked to a decreased in vitro cytotoxic capacity of TYK2(-/-) NK and NKT cells toward tumor-derived cells. RAG2/TYK2 double-knockout mice succumbed to A-MuLV-induced leukemia/lymphoma faster than RAG2(-/-)TYK2(+/-) mice. This defines NK cells as key players in tumor surveillance in Abelson-induced malignancies. Our observations provide compelling evidence that TYK2 is an important regulator of lymphoid tumor surveillance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578097      PMCID: PMC529282          DOI: 10.1172/JCI22315

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

Review 1.  Cytokines and JAK-STAT signaling.

Authors:  C Schindler
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

Review 2.  The role of STATs in myeloid differentiation and leukemia.

Authors:  P J Coffer; L Koenderman; R P de Groot
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

3.  Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.

Authors:  E Jäger; M Ringhoffer; M Altmannsberger; M Arand; J Karbach; D Jäger; F Oesch; A Knuth
Journal:  Int J Cancer       Date:  1997-04-10       Impact factor: 7.396

4.  Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.

Authors:  P Peeters; S D Raynaud; J Cools; I Wlodarska; J Grosgeorge; P Philip; F Monpoux; L Van Rompaey; M Baens; H Van den Berghe; P Marynen
Journal:  Blood       Date:  1997-10-01       Impact factor: 22.113

5.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

6.  IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses.

Authors:  J Magram; S E Connaughton; R R Warrier; D M Carvajal; C Y Wu; J Ferrante; C Stewart; U Sarmiento; D A Faherty; M K Gately
Journal:  Immunity       Date:  1996-05       Impact factor: 31.745

Review 7.  STATs in oncogenesis.

Authors:  T Bowman; R Garcia; J Turkson; R Jove
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

8.  Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice.

Authors:  A Cerwenka; A B Bakker; T McClanahan; J Wagner; J Wu; J H Phillips; L L Lanier
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

9.  TEL-JAK2 transgenic mice develop T-cell leukemia.

Authors:  C Carron; F Cormier; A Janin; V Lacronique; M Giovannini; M T Daniel; O Bernard; J Ghysdael
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

10.  Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity.

Authors:  M J Visseren; M Koot; E I van der Voort; L A Gravestein; H J Schoenmakers; W M Kast; M Zijlstra; C J Melief
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-02
View more
  27 in total

Review 1.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

2.  Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.

Authors:  Bin Zhao; Sabyasachi Bhattacharya; Qiujing Yu; Serge Y Fuchs
Journal:  Leuk Lymphoma       Date:  2017-05-15

3.  Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.

Authors:  E Waanders; B Scheijen; M C J Jongmans; H Venselaar; S V van Reijmersdal; A H A van Dijk; A Pastorczak; R D A Weren; C E van der Schoot; M van de Vorst; E Sonneveld; N Hoogerbrugge; V H J van der Velden; B Gruhn; P M Hoogerbrugge; J J M van Dongen; A Geurts van Kessel; F N van Leeuwen; R P Kuiper
Journal:  Leukemia       Date:  2016-10-13       Impact factor: 11.528

4.  NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity.

Authors:  Natalija Simonović; Agnieszka Witalisz-Siepracka; Katrin Meissl; Caroline Lassnig; Ursula Reichart; Thomas Kolbe; Matthias Farlik; Christoph Bock; Veronika Sexl; Mathias Müller; Birgit Strobl
Journal:  J Immunol       Date:  2019-02-04       Impact factor: 5.422

5.  Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish.

Authors:  Sara M N Onnebo; Parisa Rasighaemi; Janani Kumar; Clifford Liongue; Alister C Ward
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

6.  Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis.

Authors:  Qing-Xiang Amy Sang; Yan-Gao Man; You Me Sung; Zahraa I Khamis; Lihua Zhang; Mi-Hye Lee; Stephen W Byers; Ziad J Sahab
Journal:  Clin Exp Metastasis       Date:  2011-11-25       Impact factor: 5.150

Review 7.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.

Authors:  Raimund M Vielnascher; Eva Hainzl; Nicole R Leitner; Michael Rammerstorfer; David Popp; Agnieszka Witalisz; Rita Rom; Marina Karaghiosoff; Thomas Kolbe; Simone Müller; Thomas Rülicke; Caroline Lassnig; Birgit Strobl; Mathias Müller
Journal:  Transgenic Res       Date:  2014-04-03       Impact factor: 2.788

9.  The role of Tyk2 in regulation of breast cancer growth.

Authors:  Qifang Zhang; Jamie L Sturgill; Maciej Kmieciak; Karol Szczepanek; Marta Derecka; Catherine Koebel; Laura J Graham; Yun Dai; Shuang Chen; Steven Grant; Joanna Cichy; Kazuya Shimoda; Ana Gamero; Masoud Manjili; Harry Bear; Daniel Conrad; Andrew C Larner
Journal:  J Interferon Cytokine Res       Date:  2011-08-24       Impact factor: 2.607

10.  Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.

Authors:  Andrea Hoelbl; Boris Kovacic; Marc A Kerenyi; Olivia Simma; Wolfgang Warsch; Yongzhi Cui; Hartmut Beug; Lothar Hennighausen; Richard Moriggl; Veronika Sexl
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.